Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature.
Recent reports document resolution of human parvovirus B19-related pure red blood cell aplasia (PB19-PRCA) in HIV-infected patients upon commencement of highly active antiretroviral therapy (HAART). This article describes a patient with PB19-PRCA who, despite fully suppressive HAART, required cyclic administration of intravenous human immunoglobulin over a period of 17 months before PB19 seroconversion and subsequent resolution of relapsing severe anemia. All reports in the English literature describing PB19-related hematologic abnormalities in the post-HAART era are also described herein.
Morelli
P
P
Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via GB Grassi 74, 20157, Milan, Italy. paola.morelli@unimi.it
Bestetti
G
G
Longhi
E
E
Parravicini
C
C
Corbellino
M
M
Meroni
L
L
D000740:Anemia / Q000821:virology*; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000150:complications* / Q000821:virology*; D016732:Parvovirus B19, Human / Q000302:isolation & purification*
D016756:Immunoglobulins, Intravenous